Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial - Mackey, J R; Martin, M; Pienkowski, T; Rolski, J; Guastalla, J P; Sami, A (Lancet Oncol, 2013)